Safety and immunogenicity of CVD 1208S, a live, oral ΔguaBA Δsen Δset Shigella flexneri 2a vaccine grown on animal-free media

Human Vaccines

Volumn 3, Issue 6, 2007, Pages 268-275

  Kotloff, Karen L ^a,c   Simon, Jakub K ^a   Pasetti, Marcela F ^a   Sztein, Marcelo B ^a   Wooden, Stacey L ^a   Livio, Sofie ^a   Nataro, James P ^a   Blackwelder, William C ^a   Barry, Eileen M ^a   Picking, Wendy ^b   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c University of Medicine School of Medicine   (United States)

Author keywords

Clinical trial; Mucosal immunity; Oral vaccine; Phase 1; Shigella

Indexed keywords

AMPICILLIN; BACTERIAL ANTIGEN; CIPROFLOXACIN; CVD 1208 S; GAMMA INTERFERON; GUANINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LACTOFERRIN; PLACEBO; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG FECES LEVEL; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HOSPITAL PATIENT; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; NORMAL HUMAN; PROPHYLAXIS; SHIGELLA FLEXNERI; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS STRAIN;

EID: 37649000904     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4746     Document Type: Article

References (50)

1. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651-66.
2. Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD. Levine MM. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 2004; 190:1745-54.
3. Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang MS, Levine MM. Engineered ΔguaBA, ΔvirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity and potential efficacy as a mucosal vaccine. Infect Immun 1996; 64:3055-61.
4. Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J Infect Dis 1995; 172:1408-10.
5. Fasano A, Noriega FR, Maneval DR, Jr., Chanasongcram S, Russell R, Guandalini S, Levine MM. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 1995; 95:2853-61.
6. Henderson IR, Czeczulin J, Eslava C, Noriega F, Nataro JP. Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect Immun 1999; 67:5587-96.
7. Behrens M, Sheikh J, Nataro JP. Regulation of the overlapping pic/set locus in Shigella flexneri and enteroaggregative Escherichia coli. Infect Immun 2002; 70:2915-25.
8. Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG, Jr. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 1995; 63:4721-8.
9. Zoon KC. Center for Biologics Evaluation and Research Letter to Manufacturers of Biological Products. Recommendations Regarding Bovine Spongioform Encephalopathy (BSE). April 19, 2000.
10. Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 1996; 64:4542-8.
11. Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med 1983; 309:1606-15.
12. Levine MM, Black RE, Clements ML, Lanata C, Sears S, Honda T, Young CR, Finkelstein RA. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun 1984; 43:515-22.
13. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectiviry. Vaccine 1995; 13:1488-94.
14. Miller JR, Barrett LJ, Kotloff K, Guettant RL. A rapid test for infectious and inflammatory enteritis. Arch Intern Med 1994; 154:2660-4.
15. Pickering LK, DuPont HL, Olarte J, Conklin R, Ericsson C. Fecal leukocytes in enteric infections. Am J Clin Pathol 1977; 68:562-5.
16. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 2000; 68:1034-9.
17. Picking WL, Mertz JA, Marquart ME, Picking WD. Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC. Protein Expr Purif 1996; 8:401-8.
18. Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB. Production of IFNγ and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 2000; 164:2221-32.
19. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, Levine MM. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis 1994; 170:1508-17.
20. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 2007; 25:1416-25.
21. Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM. Evaluation of the safety, immunogenicity and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995; 13:495-502.
22. Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 2006; 24:3727-34.
23. Coster TS, Hoge CW, Van de Verg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999; 67:3437-43.
24. Aliprantis AO, Weiss DS, Radolf JD, Zychlinsky A. Release of Toll-like receptor-2-activating bacterial lipoproteins in Shigella flexneri culture supernatants. Infect Immun 2001; 69:6248-55.
25. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
26. Girardin SE, Jehanno M, Mengin-Lecreulx D, Sansonetti PJ, Alzari PM, Philpott DJ. Identification of the critical residues involved in peptidoglycan detection by Nod1. J Biol Chem 2005; 280:38648-56.
27. Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, Schreiber S. TNFα and IFNγ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124:1001-9.
28. Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ. Invasive Shigella flexneri activates NF-κB through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165:903-14.
29. Zychlinsky A, Kenny B, Ménard R, Prévost M-C, Holland IB, Sansonetti PJ. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol Microbiol 1994; 11:619-27.
30. Suzuki T, Nakanishi K, Tsutsui H, Iwai H, Akira S, Inohara N, Chamaillard M, Nunez G, Sasakawa C. A novel caspase-1/toll-like receptot 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages. J Biol Chem 2005; 280:14042-50.
31. Girardin SE, Travassos LH, Herve M, Blanor D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003; 278:41702-8.
32. Arondel J, Singer M, Matsukawa A, Zychlinsky A, Sansonetti PJ. Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental Shigellosis. Infect Immun 1999; 67:6056-66.
33. Pedron T, Thibault C, Sansonetti PJ. The invasive phenotype of Shigella flexneri directs a distinct gene expression pattern in the human intestinal epithelial cell line Caco-2. J Biol Chem 2003; 278:33878-86.
34. Martino MC, Rossi G, Martini I, Tattoli I, Chiavolini D, Phalipon A, Sansonetti PJ, Bernardini ML. Mucosal lymphoid infiltrate dominates colonic pathological changes in murine experimental shigellosis. J Infect Dis 2005; 192:136-48.
35. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil elastase targets virulence factors of enterobacteria. Nature 2002; 417:91-4.
36. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, Takeda K, Zychlinsky A. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000; 12:581-90.
37. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004; 4:953-64.
38. Snapper CM, Zelazowski P, Rosas FR, Kehry MR, Tian M, Baltimore D, Sha WC. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 1996; 156:183-91.
39. Kojima H, Aizawa Y, Yanai Y, Nagaoka K, Takeuchi M, Ohta T, Ikegami H, Ikeda M, Kurimoto M. An essential role for NF-κB in IL-18-induced IFNγ expression in KG-1 cells. J Immunol 1999; 162:5063-9.
40. Corn RA, Aronica MA, Zhang F, Tong Y, Stanley SA, Kim SR, Stephenson L, Enerson B, McCarthy S, Mora A, Boothby M. T cell-intrinsic requirement for NF-κB induction in postdifferentiation IFNγ production and clonal expansion in a Th1 response. J Immunol 2003; 171:1816-24.
41. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005; 6:1198-205.
42. Raqib R, Ljungdahl A, Lindberg AA, Andersson U, Andersson J. Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut 1996; 38:328-36.
43. Raqib R, Qadri F, SarkEr P, Mia SM, Sansonnetti PJ, Albert MJ, Andersson J. Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults. Scand J Immunol 2002; 55:414-23.
44. Black RE, Levine MM, Clements ML, Losonsky G, Herrington D, Berman S, Formal SB. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. JID 1987; 155:1260-5.
45. Cohen D, Green MS, Block C, Slepon R, Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 1991; 29:386-9.
46. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997; 349:155-9.
47. Formal SB, Oaks EV, Olsen RE, Wingfield Eggleston M, Snoy PJ, Cogan JP. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 1991; 164:533-7.
48. Mel DM, Terzin AL, Vuksic L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull WHO 1965; 32:647-55.
49. Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995; 345:949-52.
50. DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972; 125:12-6.